Full name
A Multicentre, Randomized, Double-Blind, Placebo Controlled, Dose Finding, Parallel Group, Phase 2 Study of an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
NCT Number
NCT06748053
Geography
US
Locations
United States
Primary Endpoints
Part A: Change from baseline in the fraction of exhaled nitric oxide (FeNo). Baseline (Day 1) and at 2, 4, 8, 12, 20 and 26 weeks
External Link
https://clinicaltrials.gov/study/NCT06748053
Order
6
Disease
Version
Phase
2
Status
Recruiting